|Home | About | Journals | Submit | Contact Us | Français|
Tourette Syndrome (TS) is a developmental disorder that has one of the highest familial recurrence rates among neuropsychiatric diseases with complex inheritance. However, the identification of definitive TS susceptibility genes remains elusive. Here, we report the first genome-wide association study (GWAS) of TS in 1285 cases and 4964 ancestry-matched controls of European ancestry, including two European-derived population isolates, Ashkenazi Jews from North America and Israel, and French Canadians from Quebec, Canada. In a primary meta-analysis of GWAS data from these European ancestry samples, no markers achieved a genome-wide threshold of significance (p<5 × 10−8); the top signal was found in rs7868992 on chromosome 9q32 within COL27A1 (p=1.85 × 10−6). A secondary analysis including an additional 211 cases and 285 controls from two closely-related Latin-American population isolates from the Central Valley of Costa Rica and Antioquia, Colombia also identified rs7868992 as the top signal (p=3.6 × 10−7 for the combined sample of 1496 cases and 5249 controls following imputation with 1000 Genomes data). This study lays the groundwork for the eventual identification of common TS susceptibility variants in larger cohorts and helps to provide a more complete understanding of the full genetic architecture of this disorder.
Tourette Syndrome (TS) is a chronic, childhood-onset neuropsychiatric disorder characterized by multiple motor tics and at least one phonic tic that persist for greater than one year.1-2 TS has a population prevalence of ~0.3-0.8%, and, like many neurodevelopmental disorders, occurs more frequently in boys, with male:female ratios ranging between 3:1-4:1.3-4 It is frequently accompanied by a wide range of additional psychiatric co-morbidities, in particular obsessive-compulsive disorder (OCD) and attention-deficit hyperactivity disorder (ADHD).5 TS causes substantial physical and psychosocial morbidity in children and adolescents, and can produce lifelong disability in severe cases.6-7
Twin and family studies have repeatedly demonstrated that TS is highly heritable.8 First-degree relatives of affected individuals have a 5-15-fold increased risk of TS compared to that of the general population, representing one of the highest familial recurrence risks among common neuropsychiatric diseases.3, 9 However, despite this strong familiality, identification of TS susceptibility genes has been challenging. Linkage analyses have produced inconsistent results, although a recent study combining multi-generational families with affected sibling pairs has identified at least one major TS locus on chromosome 2p.10 Multiple candidate genes have also been proposed, although none have been consistently replicated.8 Mutations in the strongest TS candidate genes (SLITRK1, CNTNAP2, and HDC) have been found only in single families or a small number of individuals, suggesting that, if truly causative, they account for only a small proportion of TS cases.11-15 Thus, additional gene-finding strategies are needed. Here, we report the first TS GWAS in a large cohort of samples of general European ancestry, as well as two European-derived population isolates, Ashkenazi Jews from the US and Israel (AJ) and French Canadians from Quebec, Canada (FC), and two closely related Latin American population isolates, the Central Valley of Costa Rica (CVCR) and Antioquia, Colombia (ANT).
1998 TS cases were recruited from 20 sites in the US, Canada, UK, Netherlands, Israel, Costa Rica and Colombia and divided into four strata based on self-reported ancestry: 1) 1252 European ancestry, non-isolate cases from North America and Europe (EU); 2) 210 Ashkenazi Jewish cases from the US and Israel (AJ); 3) 302 French Canadian cases (FC); 4) Cases from two closely-related population isolates from the Central Valley of Costa Rica (CVCR) (n=137) and Antioquia, Colombia (ANT) (n=97) (Supplementary Methods). Inclusion criteria required a TS Classification Study Group (TSCSG) diagnosis of definite TS (a DSM-IV-TR diagnosis of TS plus tics observed by an experienced clinician)16, and available genomic DNA extracted either from blood or cell lines. Exclusion criteria consisted of a history of intellectual disability (ID), tardive tourettism, or other known genetic, metabolic or acquired tic disorders. Subjects from 17 of the 20 sites were assessed for a lifetime diagnosis of TS, OCD and ADHD using a standardized and validated semi-structured interview that has high validity and reliability for TS (κ=1.00) and OCD (κ=0.97).10 Subjects from the other 3 sites were assessed only for a lifetime diagnosis of definite TS.
5403 European ancestry controls were derived primarily from cohorts of previously genotyped, unselected population controls (Supplementary Methods, Table S1). These included 3212 controls from the Illumina Genotype Control Database genotyped on the Illumina HumanHap550v1/v3 platforms (www.Illumina.com, Illumina, San Diego, CA, USA), 1288 controls from the Studies of Addiction: Genetics and Environment (SAGE) cohort 17-19 genotyped on the Illumina HumanHap1Mv1_C, and 653 Dutch ancestry controls genotyped on the Illumina HumanHap550v120. An additional 298 German and Dutch EU controls were genotyped simultaneously with the TS case samples, including 48 duplicates from the Dutch 550v1 control cohort, to facilitate cross-platform and cross-facility comparisons.
297 FC and 380 ANT ancestry-matched controls were collected in parallel with their respective cases (Supplementary Methods). ANT controls were used for analysis of both ANT and CVCR cases given their shared ancestry.21-22 All participants 18 years of age and older gave informed consent. Individuals under 18 years of age gave assent after a parent signed a consent form on their behalf. The research project was approved by the Ethics Committees of each participating site.
Genotyping of 908 of the 1252 EU cases and all population-isolate cases (AJ, FC, ANT, CVCR), as well as 298 EU and all FC and ANT controls, was conducted on the Illumina Human610-Quadv1_B SNP array (Illumina, San Diego, CA, USA) at the Broad Institute of Harvard and MIT (Cambridge, MA, USA) in two batches using standard protocols. Samples were randomized across plates and batches both by originating site and case-control status. Genotype calling was performed using BeadStudio (Illumina, San Diego, CA). 432 EU cases were genotyped on the Illumina HumanCNV370-Duo_v1 at the Yale Center for Genome Analysis (New Haven, CT, USA), including 88 duplicate EU samples overlapping with those genotyped on the 610-Quad platform to allow for cross-platform checks of concordance.
Quality control (QC) analyses were performed using PLINK v1.0723 and EIGENSTRAT24. In addition to standard QC protocols, particular detail focused on cross-platform comparisons of concordance, allele frequency and differential missingness, given the use of control samples genotyped previously on different Illumina platforms (full details and ordered QC pipeline available online, Figure S1). In general, two thresholds were used for SNP QC: a more stringent threshold at which SNPs were removed, and a second liberalized threshold for which SNPs were flagged and re-examined later for potential QC-related bias. All flagged SNPs with p<1×10−3 in any analysis are annotated in Tables S2-S4.
Sample and SNP QC were initially performed within each platform separately (Figure S1). Samples were removed for autosomal call rates <98%, discrepancy between phenotypic and genetic sex, and indeterminate genetic sex. In addition, all 151 cases from one site were removed due to increased rates of missing SNP data relative to other sites (Figure S2). Platform-specific SNP QC included removing monomorphic SNPs, CNV-targeted SNP probes, SNPs with genotyping rate <98%, and strand-ambiguous SNPs with significant allele frequency differences or aberrant LD correlations with adjacent SNPs based on the entire HapMap2 reference panel. Concordance was checked between 82 duplicates genotyped both on the 610-Quad (Broad) and 370K (Yale), as well as 41 duplicates genotyped on the 610Quad and 550v1. In addition, concordance was examined in HapMap duplicates from the Illumina database genotyped on 2 or more platforms used in this study. No SNPs were identified with significant association between the two 610-Quad genotyping batches.
After merging samples from all platforms, SNPs with an MAF difference >0.15 between case-case or control-control platforms were flagged, as were SNPs with >1% Mendelian errors in a parallel sample of 400 OCD trios genotyped simultaneously with the TS cases (Stewart et al., accompanying manuscript). Any SNP not present on the three major common platforms (550v1, 610-Quad, 1M) was removed, leaving 496 877 SNPs for population-specific QC.
Multi-dimensional scaling (MDS) analysis was used to exclude duplicate and related samples as well as samples of non-European descent (other than the CVCR/ANT samples, which were set aside for subpopulation-specific QC) (Figure S3). Remaining EU and European-derived isolate samples were separated into three strata (EU, AJ and FC) based on observed genetic ancestry and source population (Figures S4-S6). Within each of the MDS-defined genetic subpopulations, additional outliers were removed for excess low-level relatedness, abnormal average heterozygosity or inadequate case-control matching. The final European ancestry sample contained 1285 cases and 4964 controls (EU: 778 cases, 4414 controls; AJ: 242 cases, 354 controls; FC: 265 cases, 196 controls) (Table 1; Figure S1). The final CVCR/ANT sample consisted of 211 cases (87 ANT, 124 CVCR) and 285 ANT controls.
Subpopulation specific SNP QC included removal of SNPs with HWE p<10−10 in controls (flagged for HWE p<10−5) and two additional cross-platform QC steps to remove SNPs with differential missingness between cases and controls across the 5 Illumina datasets (Figure S7). The final number of SNPs for meta-analyses across all populations was 484 295 SNPs.
Four ancestry-stratified association analyses were performed using PLINK version 1.0723 employing logistic regression under an additive model with significant subpopulation-specific MDS dimensions included as covariates to control for residual population stratification. Strata were then combined in a case-weighted meta-analysis in METAL25 assuming a fixed-effects model. For X-chromosome SNPs, males and females were analyzed separately first and subsequently combined by meta-analysis (Supplementary Methods). For all SNPs, two meta-analyses were conducted: a primary analysis with the European-derived strata only (EU, AJ, FC), and an exploratory, secondary meta-analysis including the CVCR/ANT Latin American samples. Heterogeneity was assessed using Cochran’s Q and I2 statistics.
Expression quantitative trait loci (eQTL) data from lymphoblast cell lines (LCLs), cerebellum, and frontal cortex were generated as described previously.26-27 Similarly, methylation QTLs (mQTLs), which represent SNPs that are associated with variation in genome-wide patterns of methylation, were derived from adult cerebellum.28 The top distribution of GWAS SNPs from the primary meta-analysis, 412 LD-pruned SNPs with p<0.001, were tested for eQTL or mQTL enrichment compared to 1000 randomly-drawn, LD-pruned sets of allele-frequency matched SNPs taken from the set of typed SNPs on the Illumina 550K (Supplementary Methods). The number of eQTLs (or mQTLs) in each simulated set yielded an empirical distribution and enrichment p-value, calculated as the proportion of randomized sets in which the eQTL/mQTL count matched or exceeded the actual observed count in the list of top SNP associations. A similar analysis was performed to test for enrichment of missense SNPs or SNPs within a gene as defined by dbSNP annotation.
Imputation of SNPs from the 1000 Genomes Project was performed using IMPUTE229 and haplotypes from all 1,092 individuals in the 1000 Genomes June 2011 Data Release30 as a reference dataset (Supplementary Methods). Post-imputation QC and allelic dosage analysis were conducted in each subpopulation separately in PLINK followed by case-weighted meta-analysis in METAL.
After QC filtering, 1285 cases and 4964 controls remained across the three European ancestry strata (EU, AJ, FC). Examination of quantile-quantile (Q-Q) plots and genomic control λ values of the individual subpopulation-specific analyses revealed no evidence of residual population stratification or systematic technical artifact (EU, λ=1.011; AJ, λ=0.993; FC, λ=0.971; Figure S8a-c). The Latin-American population isolate stratum (CVCR/ANT) showed a small inflation of the median test statistic (λ=1.044), indicative of some residual stratification between CVCR and ANT samples (Figure S6). However, no SNPs in this subpopulation-specific analysis had extreme p-values outside the expected null distribution (Figure S8d).
In the primary meta-analysis of European-derived samples, no SNP surpassed a genome-wide significant threshold of p<5.0×10−8 (Figure 1). The top 5 LD-independent loci are annotated in Table 2; full annotation of all SNPs with p<1×10−3 are provided in Table S2. The SNP with the strongest signal, rs7868992, lies on chromosome 9q32 within an intron of COL27A1 (p=1.85 ×10−6; Figure S9). The other four top independent GWAS signals include rs6539267, an intronic SNP within POLR3B on chromosome 12q23 (p=7.41 ×10−6; Figure S10); rs13063502, a SNP that lies in a 1.7 Mb intergenic region on chromosome 3q13 (p=8.96 ×10−6; Figure S11); rs7336083, located on chromosome 13q31 within a 1.9 Mb intergenic region between SLITRK6 and SLITRK112 (p=9.49 ×10−6; Figure S12); and rs769111, an intergenic SNP on chromosome 7p21 between THSD7A and TMEM106B (p=1.20 ×10−5;Figure S13). No effect-size heterogeneity was present between the three European-derived subpopulations for SNPs rs7868992, rs6539267 and rs7336083 (Figures S9-13). rs13063592 and rs769111 demonstrated moderate heterogeneity (I2=45.4% and 64.2%, respectively), though the direction of effect was consistent across the EU, AJ and FC populations.
In the secondary meta-analysis combining all 1496 TS cases and 5249 controls (European ancestry samples plus 211 cases and 285 controls from the Latin American CVCR/ANT samples), the strongest association was again found in rs7868992 within COL27A1 on 9q32 (combined p= 2.94 × 10−8; Table S5, Figures S9c,S14). Examination of an LD-pruned set of top SNPs from the primary meta-analysis (412 SNPs with p<1 × 10−3) found a slight, but non-significant increase in the number of SNPs with the same direction of effect in the CVCR/ANT analysis (223/412, p=0.052, one-sided binomial sign test; Tables S2,S3).
Imputation was performed using 1000 Genomes Project data30 to identify additional supportive SNPs within the top signals from each meta-analysis. Q-Q plots of the primary and secondary meta-analyses incorporating imputed data demonstrated minimal inflation of the median test statistic (Figure S15). No imputed SNPs in either meta-analysis surpassed the genome-wide significant threshold of p< 5×10−8. rs7868992 remained the top SNP overall, although its p-value dropped to 3.61 × 10−7 following imputation (Figure S9c).
Since many of the top signals in the primary meta-analysis (p<0.001) appeared to lie within or adjacent to known brain-expressed genes (Table S2), we sought functional evidence to support the observed associations by evaluating the effect of these SNPs on transcriptional expression and DNA methylation levels. We annotated all GWAS SNPs with expression QTL (eQTL) information derived previously from lymphoblast cell lines (LCLs), adult cerebellum, and frontal cortex as well as methylation QTL (mQTL) information from adult cerebellum (Table S2). The top LD-independent SNPs (412 SNPs with p<0.001) were subsequently tested for eQTL and mQTL enrichment. These top SNPs from the primary analysis were nominally enriched for eQTLs in frontal cortex (empirical p-value=0.045) with a trend toward enrichment in cerebellum (p=0.077), but no enrichment in LCLs (p=0.712) (Figure 2a-c). The highest association signals were also nominally enriched for cerebellar mQTLs (p=0.011) (Figure 2d). A similar test for SNPs located within gene loci found no enrichment (p=0.258), though missense SNPs demonstrated a borderline enrichment (p=0.098).
As an additional exploratory analysis, we examined the associations of SNPs within 50kb of 24 previously reported candidate TS genes (Tables S6-S7). We found no excess of lower p-values among the 2135 SNPs within these genes compared to those expected under the null, suggesting that these candidate genes are not enriched for common SNPs associated with TS (Figure S16). One signal in the primary European ancestry meta-analysis had a nominal p<1 ×10−3 (rs10277969 within CNTNAP2, p=7.8 ×10−4), but this locus did not survive a Bonferroni correction for gene size (266 LD-independent SNPs within CNTNAP2, corrected p=.21).
Although the current sample of 1496 TS cases and 5249 controls is the largest studied to date, no loci in our analysis reached the widely accepted statistical threshold for genome-wide significance of p≤5 × 10−8.31-32 This observation is not surprising, given that GWA studies for other highly heritable neuropsychiatric diseases (e.g., autism, bipolar disorder and schizophrenia) have required sample sizes of 5000-10000 cases to identify definitive common risk alleles with modest effect sizes (odds ratios <1.3).33 However, the marginal enrichment of functional brain variants (eQTLs and mQTLs) within the top loci in the primary meta-analysis (Figure 2) suggests that a subset of top signals in our analysis are true associations that may contribute to TS risk through effects on gene expression and methylation. In particular, the trend toward enrichment of frontal cortex eQTLs compared to eQTLs in cerebellum and LCLs is anatomically consistent with the hypothesis that TS is caused by abnormalities in fronto-striatal circuitry.34 Nonetheless, given the nominal significance of these enrichment results, further studies in larger samples are needed before drawing definitive conclusions.
The strongest signal in the primary European ancestry meta-analysis, rs7868992, was also the top locus in the secondary meta-analysis, which incorporated an additional 496 non-European cases and controls from the CVCR and ANT Latin American population isolates (Figure S9). In this combined analysis, rs7868992 initially achieved a p-value of 2.94 ×10−8, surpassing the threshold for genome-wide significance. However, following imputation, this signal decreased to p=3.61 ×10−7, most likely due to the incorporation of imputed data from the 148 European-ancestry cases genotyped on the Illumina 370K, which does not directly interrogate rs7868992. Nonetheless, rs7868992 performed robustly on the other Illumina platforms used in this study based on review of the normalized intensity plots (Figure S9d) and the 100% concordance rate in all cross-platform comparisons of this SNP in HapMap duplicates from the Illumina database (Supplementary Materials). Therefore, rs7868992 remains a promising candidate, but cannot be considered a TS susceptibility variant unless it is replicated in an independent sample.
rs7868992 is located within an intron of COL27A1, the Type XXVII collagen alpha chain gene. COL27A1 is a fibrillar collagen primarily expressed in cartilage, though it is expressed in the cerebellum during many stages of human development.35-36 While non-fibrillar collagens have been implicated in various neurodevelopmental processes (e.g. axon guidance and synaptogenesis), the function of COL27A1 in the developing nervous system is unknown.37
The second top SNP in the primary analysis, rs6539267, is located on chromosome 12q23 within an intron of POLR3B. This gene encodes the second largest subunit of RNA polymerase III, which transcribes eukaryotic non-coding RNAs including tRNAs, small rRNAs and microRNAs.38 Recessive mutations in POLR3B cause hypomyelinating leukodystrophy with a severe neurological phenotype (developmental delay, spasticity, dysarthria and ataxia), though no reported tics.39-40 Both the secondary meta-analysis and imputed data provide additional support for this locus, and expand the region of LD to ~300kb, including adjacent genes CKAP4, TCP11L2 and RFX4 (Table S5, Figure S10).
The other 3 top loci in the primary analysis are located within large intergenic regions. rs13063502 on 3q13.1 lies between the non-coding cDNA FLJ25363 and PVRL3, which resides 1.5 Mb telomeric to rs13063502 and is expressed primarily in placenta and testis.41 rs769111 on 7p21.3 is situated between THSD7A, a gene expressed almost exclusively in developing endothelial cells42, and TMEM106B, a gene recently associated with fronto-temporal dementia with TDP-43 inclusions (FTD-TDP), whose primary function in the brain remains to be elucidated.43 Lastly, rs7336083 lies in a 1.9 Mb intergenic region between SLITRK1 and SLITRK6 on chromosome 13q31. While SLITRK1 is an a priori candidate TS susceptibility gene based on previous identification of both rare functional variants12 and common haplotypes44 in TS patients, functional annotation indicates that rs7336083 is a cerebellar eQTL of SLITRK6. Candidate gene analysis of all genotyped SNPs within 50 kb of SLITRK1 identified no nominally associated SNPs (Table S9), including two SNPs recently reported to be associated with TS in a separate European-ancestry sample45 (rs9593835 and rs9546538; p=0.52 and p=0.98 respectively in this study). Of note, the association signals in rs7336083 and rs13063502 decreased in the secondary meta-analysis (Figures S11-S12, Table S3). It remains to be determined whether these signal reductions are indicative of false positive associations, random signal fluctuations, or genetic heterogeneity between the European ancestry samples and the Latin American CVCR/ANT samples used in the secondary analysis.
This study has several potential limitations. The use of shared controls genotyped previously on different Illumina platforms creates the possibility of a systematic technical bias. To address this concern, we employed stringent, iterative individual platform QC procedures, tests of cross-platform concordance using sample duplicates, and additional extensive testing for differential missing data between platforms. We also excluded SNPs known to perform differentially across Illumina platforms that can cause spurious results if not recognized (N. Cox, personal communication).46 The minimal inflation of the median test statistic in the primary meta-analysis (λGC= 0.996), as well as the nominal enrichment of the top signals for SNPs with known functional significance in brain, argues that these efforts effectively mitigated this potential confound.
Second, there was residual population stratification between the TS cases from the Central Valley of Costa Rica (CVCR) and control samples from Antioquia, Colombia (ANT). Although initially thought to have arisen from common founders22, recent studies suggest that these populations have slight differences in Native American ancestry (A. Ruiz-Linares, N. Freimer, personal communication). Though the resulting λGC of 1.04 in the CVCR/ANT subpopulation analysis is relatively small and thus is likely not to introduce significant bias in a meta-analysis, we chose to reserve these non-European samples for a secondary analysis to provide supportive evidence to individual candidate susceptibility loci. While we did not find significant evidence for a consistent direction of effect between the top signals in the primary European ancestry meta-analysis and those in the CVCR/ANT subpopulation analysis, it is important to note that the CVCR/ANT samples are an admixed population with a significant proportion of non-European ancestry47, and thus do not represent a true replication sample for the European ancestry meta-analysis.
In summary, this study represents the first GWAS of TS. Despite the lack of genome-wide significant loci, the study provides an important foundation for future replication efforts and lays the groundwork for the eventual identification of definitive common TS susceptibility variants. The data also contribute to the still nascent understanding of the underlying genetic architecture of TS, which is likely to include genetic variation across the allelic frequency spectrum.13, 45, 48-50 Our results also parallel those of other common neuropsychiatric disorders, for which increased sample sizes have generated significant findings for both common and rare variants that together provide key insights into previously unknown disease mechanisms.51-53 Finally, the current data will facilitate examination of the proposed genetic relationships between TS and its common co-occurring conditions, OCD and ADHD8, as well as those from additional psychiatric disorders33, with the goal of identifying the biological pathways shared by these common neurodevelopmental conditions.
The authors are grateful to all the patients with Tourette Syndrome who generously agreed to participate in this study. Furthermore, the members of the Tourette Syndrome Association International Consortium for Genetics are deeply indebted to the Tourette Syndrome Association for their guidance and support. The authors would also like to thank Libby Bernier and Janelle Alabiso for their assistance in manuscript preparation and Stephan Ripke for help with meta-analysis figures. This work was supported by a grant from the Judah Foundation, NIH grants NS40024 to DLP and the Tourette Syndrome Association International Consortium for Genetics, NIH grant NS16648 and a grant from the Tourette Syndrome Association to DLP, NIH grant NS037484 to NBF, NIH grant NS043538 to AR-L, and an American Academy of Neurology Foundation grant and NIH grant MH085057 to JMS. The Broad Institute Center for
Genotyping and Analysis was supported by grant U54 RR020278 from the National Center for Research Resources. Support was also provided by the New Jersey Center for Tourette Syndrome & Associated Disorders (through New Jersey Department of Health and Senior Services: 08-1827-FS-N-0) to GAH and JAT and P01MH049351, R01MH061940, K05MH076273 and T32MH018268 to JFL. Funding support for generation of the eQTL data was provided by the UK Medical Research Council and the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services project Z01 AG000932-02. Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided through the NIH Genes, Environment and Health Initiative [GEI] (U01 HG004422). SAGE is one of the genome-wide association studies funded as part of the Gene Environment Association Studies (GENEVA) under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (COGA; U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392), and the Family Study of Cocaine Dependence (FSCD; R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH contract "High throughput genotyping for studying the genetic contributions to human disease" (HHSN268200782096C). The datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study_id=phs000092.v1.p1 through dbGaP accession number phs000092.v1.p.
Manuscript preparation: JM Scharf, D Yu, CA Mathews, BM Neale, SE Stewart, JA Fagerness, E Gamazon, N Freimer, NJ Cox, DL Pauls
Study design: JM Scharf, D Yu, CA Mathews, BM Neale, SE Stewart, JA Fagerness, S Purcell, P Heutink, BA Oostra, W McMahon, N Freimer, NJ Cox, DL Pauls
Data analysis: D Yu, BM Neale, JM Scharf, P Evans, E Gamazon, CK Edlund, S Service, SE Stewart, A Tikhomirov, A Pluzhnikov, A Konkashbaev, LK Davis, B Han, D Posthuma, E Eskin, C Sabatti, DV Conti, JA Knowles, NB Freimer, S Purcell, NJ Cox
Project management: JM Scharf, JA Fagerness, DL Pauls
Sample management and processing: JA Fagerness, JM Scharf, J Crane, P Moorjani, DL Pauls
Genotyping: AT Crenshaw, MA Parkin, DB Mirel
Phenotype management: CA Mathews, JM Scharf, L Osiecki, C Illmann, SE Stewart, W McMahon, DL Pauls
Case Sample Collection: European Ancestry Samples (ordered by numbers of submitted samples): Yale University: RA King (Site PI), T Fernandez, KK Kidd, JR Kidd, JF Leckman, AJ Pakstis, MW State; Utrecht University/VU Medical Center: DC Cath (Site PI), JH Smit, P Heutink; University of Toronto: P Sandor (Site PI), CL Barr, N Phan; Massachusetts General Hospital: DL Pauls (Site PI), C Illmann, L Osiecki, JM Scharf; University of Utah: W McMahon (Site PI), G Lyon, M Leppert, J Morgan, R Weiss; Johns Hopkins School of Medicine: MA Grados (Site PI), K Anderson, S Davarya, H Singer, J Walkup; Baylor College of Medicine: J Jankovic (Site PI); Rutgers University: JA Tischfield (Site PI), GA Heiman, RA King; University of Cincinnati: DL Gilbert (Site PI); University of Groningen: PJ Hoekstra(Site PI); University College London: MM Robertson (Site PI); UCSF: CA Mathews (Site PI), VI Reus, TL Lowe, P Lee, M Rangel-Lugo; University of Rochester School of Medicine: R Kurlan (Site PI).
French Canadian Samples: University of Montreal: GA Rouleau (Site PI), S Chouinard, Y Dion, S Girard.
Ashkenazi Jewish Samples: UCSF: CA Mathews (Site PI), VI Reus, TL Lowe, M Rangel-Lugo; Shaare Zedek Medical Center: V Gross-Tsur (Site PI), Y Pollak; Hadassah Mount Scopus Hospital: F Benarroch; North Shore-Long Island Jewish Medical Center: C Budman (Site PI), R Bruun.
Central Valley Costa Rica (CVCR) Samples: UCSF: CA Mathews (Site PI), VI Reus, TL Lowe, M Rangel-Lugo; N Weiss; Hospital Nacional de Niños: LD Herrera (Site PI), R Romero, E Fournier; UCLA: N Freimer (Site PI)
Antioquia Colombian Samples: University of College London: A Ruiz-Linares (Site PI), B Kremeyer, D Campbell, H Muller; Universidad de Antioquia: G Bedoya Berrío, J Cardona Silgado, W Cornejo Ochoa, S Mesa Restrepo, A Valencia Duarte
Control Sample Collection: University Medical Center, Utrecht: R Ophoff, E Strengman; University of Bonn: M Wagner, R Moessner
eQTL and mQTL Data: C Liu; JR Gibbs and A Singleton for the North American Brain Expression Consortium ; J Hardy for the UK Human Brain Expression Database
North American Brain Expression Consortium: S Arepalli1, MR Cookson1, A Dillman1, L Ferrucci2, JR Gibbs1,3, DG Hernandez1,3, R Johnson4, DL Longo5, Michael A Nalls1, Richard O’Brien6, Andrew Singleton1, Bryan Traynor1, Juan Troncoso6, Marcel van der Brug1,7, HR Zielke4, A Zonderman8; UK Human Brain Expression Database: JA Hardy3, M Ryten3, C Smith9, D Trabzuni3, R Walker9, Mike Weale10
1Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; 2Clinical Research Branch, National Institute on Aging, Baltimore, MD, USA; 3Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; 4NICHD Brain and Tissue Bank for Developmental Disorders, University of Maryland Medical School, Baltimore, Maryland, USA; 5Lymphocyte Cell Biology Unit, Laboratory of Immunology, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA; 6Brain Resource Center, Johns Hopkins University, Baltimore, MD, USA; 7ITGR Biomarker Discovery Group, Genentech, South San Francisco, CA, USA; 8Research Resources Branch, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; 9Department of Pathology, The University of Edinburgh, Edinburgh, UK; 10Department of Medical & Molecular Genetics, King’s College London, UK
CONFLICT OF INTEREST Drs. Pauls, Scharf, Mathews, Cox, Freimer, McMahon, Heutink, Oostra, Grados, King, Rouleau, Sandor and Budman have all received research support from the NIH and the Tourette Syndrome Association (TSA) on behalf of the TSA International Consortium for Genetics (TSAICG). Drs. Scharf, Mathews and Grados have received honoraria and travel support from the TSA. Dr. Mathews is a member of the TSA Medical Advisory Board. Dr. Sandor has received support and consulting fees from Psyadon, Shire, Solway, UCB Pharma, Janssen, Eli Lilly, Pfizer, and Prestwick. Dr. Budman has been funded by Psyadon Pharmaceuticals, Otsuka Pharmaceuticals, and NINDS and is a member of the National TSA Medical Advisory Board, LI TSA and LI CHADD Medical Advisory Boards. Dr. Hoekstra has received honoraria for advice through Desitin, Eli Lilly and Shire. Dr. Dion has received honoraria from Biovail Pharma, Pfizer and Eli Lilly. Dr. Leckman has been funded by the NIH, the TSA, Talecris Biotherapeutics, Klingenstein Third Generation Foundation, John Wiley and Sons, McGraw Hill, and Oxford University Press. Dr. Walkup receives research support, travel support for paid and unpaid activities, serves in an unpaid position on the Medical Advisory Board, and receives an honorarium for an Educational Meeting from the TSA. He receives royalties from Guilford Press and Oxford Press. He received free medication and placebo from Lilly, Pfizer and Abbott for NIH funded studies. Dr. Jankovic has received research grants from the following: Allergan, Inc; Allon Therapeutics; Ceregene, Inc; Chelsea Therapeutics; Diana Helis Henry Medical Research Foundation; EMD Serono; Huntington’s Disease Society of America; Huntington Study Group; Impax Pharmaceuticals; Ipsen Limited; Lundbeck Inc; Medtronic; Merz Pharmaceuticals; Michael J Fox Foundation for Parkinson Research; National Institutes of Health; National Parkinson Foundation; Neurogen; St. Jude Medical; Teva Pharmaceutical Industries Ltd; University of Rochester; Parkinson Study Group. He has served as a consultant or advisory committee member for Allergan, Inc; Chelsea Therapeutics; EMD Serono; Lundbeck Inc; Merz Pharmaceuticals; Michael J Fox Foundation for Parkinson Research; Teva Pharmaceutical
Industries Ltd. He also serves on the editorial boards for Elsevier; Medlink: Neurology; Neurology in Clinical Practice; Neurotoxin Institute; Scientiae; UpToDate. Dr. Knowles is on the Scientific Advisory Committee for Next-Generation Sequencing of Life Technologies, Inc. and is a technical advisor to SoftGenetics, Inc.
Ms. Anderson, Dr. Barr, Dr. Benarroch, Mr. Berrío, Dr. Bruun, Mr. Campbell, Dr. Cath, Dr. Chouinard, Dr. Conti, Ms. Crane, Mr. Crenshaw, Ms. Davarya, Dr. Davis, Ms. Duarte, Mr. Edlund, Dr. Erenberg, Dr. Eskin, Dr. Evans, Mr. Fagerness, Dr. Fernandez, Mr. Fournier, Mr. Gamazon, Mr. Gibbs, Dr. Gilbert, Dr. Girard, Dr. Gross-Tsur, Dr. Han, Dr. Hardy, Dr. Heiman, Dr. Herrera, Dr. Heutink, Dr. Illmann, Dr. J Kidd, Dr. K Kidd, Mr. Konkashbaev, Dr. Kremeyer, Dr. Kurlan, Dr. Lee, Dr. Leppert, Dr. Liu, Dr. Lowe, Dr. Lyon, Dr. Mirel, Dr. Moessner, Ms. Moorjani, Mr. Morgan, Mr. Muller, Dr. Naarden, Dr. Neale, Dr. Ochoa, Dr. Ophoff, Ms. Osiecki, Dr. Pakstis, Ms. Parkin, Mr. Phan, Dr. Pluzhnikov, Dr. Pollak, Dr. Posthuma, Dr. Purcell, Dr. Rangel-Lugo, Dr. Restrepo, Dr. Reus, Ms. Rivas, Dr. Robertson, Ms. Romero, Dr. Ruiz-Linares, Dr. Sabatti, Ms. Service, Mr. Silgado, Dr. Singer, Dr. Singleton, Dr. Smit, Dr. State, Dr. Stewart, Mr. Strengman, Dr. Tikhomirov, Dr. Tischfield, Dr. Wagner, Dr. N Weiss, Dr. R. Weiss and Ms. Yu declare no potential conflicts of interest.
None of the funding agencies for this project (NINDS, NIMH, the Tourette Syndrome Association and the Judah Foundation) had any influence or played any role in a) the design or conduct of the study; b) management, analysis or interpretation of the data; c) preparation, review or approval of the manuscript.
Supplementary information is available at Molecular Psychiatry’s website.